Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy

Hepatology Communications - United Kingdom
doi 10.1002/hep4.1307
Full Text
Abstract

Available in full text

Categories
Hepatology
Date
Authors
Publisher

Wiley

Related search

Cost Effectiveness Analysis of Sofosbuvir and Ledipasvir/Sofosbuvir in Hepatitis C Virus (HCV) Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Novel NS5B Resistance‐Associated Substitution Emerges Under Failing Sofosbuvir/Ledipasvir Therapy

Clinical Liver Disease
Hepatology
2019English

Sofosbuvir, Peg Interferon & Ribavirin for Retreatment of HCV Genotype 1b Following Sofosbuvir and Ledipasvir Failure

Hepatology
MedicineHepatology
2018English

Ledipasvir and Sofosbuvir for HCV-infection in Patients Coinfected With HBV

Antiviral Therapy
Infectious DiseasesPharmacology
2016English

Ledipasvir and Sofosbuvir for Recurrent Hepatitis C After Liver Transplantation

BioScience Trends
BiochemistryHealthMedicineGeneticsMolecular Biology
2016English

“Bureaucracy & Beliefs”: Assessing the Barriers to Accessing Opioid Substitution Therapy by People Who Inject Drugs in Ukraine

Drugs: Education, Prevention and Policy
MedicineHealth
2015English

Sofosbuvir/Ledipasvir and Ribavirin Tolerability and Efficacy in Pediatric Liver Transplant Recipients

Liver Transplantation
HepatologyTransplantationSurgery
2017English

Effectiveness of 8- Or 12-Weeks of Ledipasvir and Sofosbuvir in Real-World Treatment-Naïve, Genotype 1 Hepatitis C Infected Patients

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Managing Tuberculosis in People Who Use and Inject Illicit Drugs

Bulletin of the World Health Organization
EnvironmentalPublic HealthOccupational Health
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy